

Recommendation for Promoting Antimicrobial Resistance (AMR) Countermeasures in the Basic Policy on Economic and Fiscal Management and Reform 2023

May 24, 2023
AMR Alliance Japan

Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2023

Promote countermeasures for antimicrobial resistance (AMR) with a One Health approach from perspectives including economic security and serve as a global leader in strengthening preparedness against the threat of infectious disease.

To promote infectious disease control measures to combat antimicrobial resistance (AMR), AMR Alliance Japan recommends including the above phrase in the FY2023 Basic Policy on Economic and Fiscal Management and Reform.

Every year since 2016, Japan's Basic Policies on Economic and Fiscal Management and Reform have mentioned strengthening efforts to promote AMR control and expanding systems for research, testing, and treatment. Mention of this objective was expanded in 2022 to state, "Japan will also comprehensively examine concrete methods to secure therapeutic drugs for drug-resistant bacteria such as market incentives in measures designed to counter drug resistance, draw conclusions based on these examinations, and then play a leading role in international discussions." In this manner, Japan has emphasized the importance of AMR control.

As described in the attachment titled, "Promoting Antimicrobial Resistance (AMR) Countermeasures in the Basic Policy on Economic and Fiscal Management and Reform 2023 Recommendation Background," progress is being made in measures to combat AMR both in Japan and around the world. Looking ahead to the 79th session of the UN General Assembly (UNGA 79) in 2024 and beyond, it will be crucial for Japan to fulfill its commitments to the international community in its capacity as G7 President in 2023 based on the idea that infectious disease control cannot be fully implemented by countries acting alone.

About AMR Alliance Japan AMR Alliance Japan was established in November 2018 as multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of May 2023, its members include, in alphabetical order: MSD K.K., The Children and Healthcare Project, Shionogi & Co., Ltd., Shimadzu Diagnostics Corporation, Sumitomo Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, Nippon Becton Dickinson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japan Society of Hospital Pharmacists, The Pharmaceutical Society of Japan, The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. Health and Global Policy Institute (HGPI) serves as its secretariat.